Oclacitinib works by selectively inhibiting certain enzymes called Janus kinases (JAKs), which are involved in signaling pathways that contribute to inflammation and immune responses. Specifically, oclacitinib primarily inhibits JAK1 and JAK3, which are enzymes involved in the signaling pathways of several cytokines, which are proteins that play a key role in inflammation and immune responses.

Inflammatory skin conditions, such as atopic dermatitis in dogs, involve an overactive immune response, which leads to inflammation and itching. Oclacitinib helps to reduce inflammation and itching by blocking the activity of JAK enzymes, which are involved in the signaling of various cytokines that contribute to the inflammatory response in the skin.

By inhibiting JAK enzymes, oclacitinib disrupts the signaling cascade that leads to inflammation and immune responses, thereby reducing the itching, inflammation, and other clinical signs associated with atopic dermatitis in dogs. Oclacitinib is considered a selective JAK inhibitor, meaning that it targets specific JAK enzymes and has a more focused effect on the immune response, which may result in fewer systemic side effects compared to non-selective JAK inhibitors.

It’s important to note that oclacitinib is a prescription medication for veterinary use and should only be used under the guidance and supervision of a veterinarian. The dosage, duration of treatment, and monitoring for potential side effects should be determined by a veterinarian based on the specific condition being treated and the individual patient’s health status.

Oclacitinib is a medication that works as a selective inhibitor of Janus kinases (JAKs), which are enzymes involved in signaling pathways that regulate inflammation and immune responses in the body. Specifically, oclacitinib primarily inhibits JAK1 and JAK3, which are enzymes that play a role in the signaling of various cytokines, which are proteins involved in inflammation and immune responses.

When the body encounters an inflammatory trigger, such as an allergen in the case of atopic dermatitis, JAK enzymes become activated and initiate a signaling cascade that leads to the production and release of cytokines. These cytokines then stimulate inflammation and immune responses in the body, resulting in the characteristic symptoms of the inflammatory condition, such as itching, redness, and swelling.

By selectively inhibiting JAK enzymes, oclacitinib disrupts the signaling cascade, reducing the production and release of cytokines and subsequently dampening the inflammatory response. This helps to alleviate the itching, inflammation, and other clinical signs associated with conditions like atopic dermatitis in dogs, where the immune response is overactive and causing excessive inflammation in the skin.

It’s important to note that the exact mechanism of action of oclacitinib may vary depending on the specific condition being treated and the JAK enzymes involved. Oclacitinib is a prescription medication for veterinary use and should only be used under the guidance and supervision of a veterinarian. The dosage, duration of treatment, and monitoring for potential side effects should be determined by a veterinarian based on the specific condition being treated and the individual patient’s health status.